<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903029</url>
  </required_header>
  <id_info>
    <org_study_id>NewStaR4G</org_study_id>
    <nct_id>NCT03903029</nct_id>
  </id_info>
  <brief_title>Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline</brief_title>
  <official_title>AssessmeNt of Efficacy of Low-dose rosuvaStatin in KoRean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to evaluate the efficacy of low-dose rosuvastatin (10 mg) in the 4 statin
      benefit groups requiring high- or moderate-intensity statin therapy according to the 2013
      American College of Cardiology/American Heart Association guideline in Korean population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint was percentage reduction in low-density lipoprotein (LDL) cholesterol.
      Secondary endpoints were percentage reduction in other lipids and achievement of ≥50%
      reduction in LDL cholesterol. Intention-to-treat analyses were performed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 10, 2014</start_date>
  <completion_date type="Anticipated">December 5, 2019</completion_date>
  <primary_completion_date type="Actual">July 5, 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Percentage reduction in low-density lipoprotein (LDL) cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage reduction in low-density lipoprotein (LDL) cholesterol from baseline to 8 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in other lipids</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent changes from baseline to 8 weeks in total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride (TG), non-HDL cholesterol, apolipoprotein B, apolipoprotein A1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of ≥50% reduction in LDL cholesterol</measure>
    <time_frame>8 weeks</time_frame>
    <description>Achievement of ≥50% reduction in LDL cholesterol with use of rosuvastatin 10 mg in 8 weeks</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">242</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Low-dose (10mg) rosuvastatin</arm_group_label>
    <description>Four statin benefit groups per 2013 ACC/AHA guideline in Korea</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose (10mg) rosuvastatin</intervention_name>
    <description>Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline</description>
    <arm_group_label>Low-dose (10mg) rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Four statin benefit groups per 2013 ACC/AHA guideline in Korean
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. subjects with prior history of clinical ASCVD

          2. subjects with primary elevation of LDL cholesterol ≥190 mg/dL

          3. subjects with diabetes, age 40 to 75 years, and LDL cholesterol 70 to 189 mg/dL

          4. subjects without diabetes, age 40 to 75 years, LDL cholesterol 70 to 189 mg/dL, and
             with estimated 10-year ASCVD risk ≥7.5%.

        Exclusion Criteria:

          1. history of significant statin-induced rhabdomyolysis or myopathy

          2. history of a significant hypersensitivity reaction to rosuvastatin

          3. uncontrolled diabetes mellitus (HbA1c &gt;9%)

          4. uncontrolled hypertension (systolic blood pressure &gt;190 mmHg or diastolic blood
             pressure &gt;100 mmHg)

          5. current active liver disease (alanine aminotransferase and/or aspartate
             aminotransferase &gt;2 times the upper limit of normal)

          6. chronic kidney disease (serum creatinine clearance &lt;30 ml/min)

          7. creatine kinase levels &gt;3 times the upper limit of normal

          8. use of prohibited concomitant therapies

          9. history of malignancy within the last 5 years

         10. women who were pregnant, breast-feeding or of childbearing potential without
             contraception

         11. subjects who would take any medication for purposes other than this trial within 30
             days after taking this study's medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyo-Soo Kim, MD., PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholesterol, LDL</keyword>
  <keyword>Asian</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Low-dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

